GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trex Wind Down Inc (OTCPK:TMBRQ) » Definitions » Cash-to-Debt

Trex Wind Down (Trex Wind Down) Cash-to-Debt : 4.62 (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Trex Wind Down Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Trex Wind Down's cash to debt ratio for the quarter that ended in Jun. 2023 was 4.62.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Trex Wind Down could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Trex Wind Down's Cash-to-Debt or its related term are showing as below:

TMBRQ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13   Med: 12.39   Max: 27.43
Current: 4.62

During the past 3 years, Trex Wind Down's highest Cash to Debt Ratio was 27.43. The lowest was 0.13. And the median was 12.39.

TMBRQ's Cash-to-Debt is ranked worse than
55.34% of 1527 companies
in the Biotechnology industry
Industry Median: 6.42 vs TMBRQ: 4.62

Trex Wind Down Cash-to-Debt Historical Data

The historical data trend for Trex Wind Down's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Trex Wind Down Cash-to-Debt Chart

Trex Wind Down Annual Data
Trend Dec20 Dec21 Dec22
Cash-to-Debt
12.39 23.94 27.43

Trex Wind Down Quarterly Data
Apr19 Apr20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.38 26.72 27.43 8.28 4.62

Competitive Comparison of Trex Wind Down's Cash-to-Debt

For the Biotechnology subindustry, Trex Wind Down's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Trex Wind Down's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trex Wind Down's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Trex Wind Down's Cash-to-Debt falls into.


Trex Wind Down Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Trex Wind Down's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=9.08 / (0.331 + 0)
=27.43

Trex Wind Down's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=2.52 / (0.222 + 0.323)
=4.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trex Wind Down  (OTCPK:TMBRQ) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Trex Wind Down Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Trex Wind Down's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Trex Wind Down (Trex Wind Down) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trex Wind Down Inc (OTCPK:TMBRQ) » Definitions » Cash-to-Debt
Comparable Companies
IMNN GRTX CMRA EVLO ONVO VYNE ARAV BNTC EDSA EIGR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
3 Mountain View Road, Suite 100, Warren, NJ, USA, 07059
Website
https://www.timberpharma.com
Timber Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. Its investigational therapies have mechanisms of action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing, and control) and safety profiles. The company is focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), X-linked recessive CI (XLRI) and autosomal recessive CI (ARCI), and other sclerotic skin diseases. The company's late-stage program is TMB-001., and TMB-003 is the earliest-stage program.
Executives
John Koconis director, officer: Chief Executive Officer C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Alan Mendelsohn officer: Chief Medical Officer C/O TIMBER PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE A26, WOODCLIFF LAKE NJ 07677
Edward J Sitar director 39 FLAMING ARROW ROAD, MAHWAH NJ 07430
Tardimed Sciences Llc 10 percent owner 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
David E Cohen director 3160 PORTER DRIVE, PALO ALTO CA 94304
Lubor Gaal director C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Kimberly Bragg officer: Controller C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Amir Tavakkol officer: Chief Scientific Officer C/O VIAMET PHARMACEUTICALS HOLDINGS LLC, 4505 EMPEROR BLVD., SUITE 300, DURHAM NC 27703
Michael Derby director, officer: Executive Chairman 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Zachary Rome director, officer: Executive VP, COO and Sec. C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Joseph Lucchese officer: Executive VP & CFO C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Michael Stocum director C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Linda A Broenniman director 1895 PRESTON WHITE DR, STE 250, RESTON VA 20191
Gianluca Pirozzi director C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMITON AVENUE, SUITE 100, CAMPBELL CA 95008
Timber Pharmaceuticals Llc 10 percent owner 50 TICE BOULEVARD, SUITE A26, WOODCLIFF LAKE NJ 07677